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Background: The current recommendation within integrated Community Case Management guidelines that all
children presenting with uncomplicated fever and no danger signs be followed up after three days may not be
necessary. Such fevers often resolve rapidly (usually within 48–96 h), and previous studies suggest that expectant
home care for uncomplicated fever can be safely recommended. We aim to determine the non-inferiority of a
conditional versus a universal follow-up visit for these children.
Methods: We are conducting a cluster-randomized, community-based, non-inferiority trial enrolling ~4300 children
(ages 2–59 months) presenting to community health workers (CHWs) with uncomplicated fever in Tanganyika
Province, Democratic Republic of the Congo. Clusters (n = 28) of CHWs are randomized to advise caretakers of such
children to either 1) return for a follow-up visit on Day 3 following the initial consultation (Day 1), regardless of
illness resolution (as per current guidelines) or 2) return for a follow-up visit on Day 3 only if the child’s signs have
not resolved. Enrolled children are followed up at Day 7 for a repeat assessment and recording of the primary
outcome of the study, “failure”, which is defined as having fever, diarrhea, pneumonia or decline of health status
(e.g. hospitalization, presenting danger signs, or death).
Discussion: The results of this trial will be interpreted in conjunction with a similarly designed trial currently
ongoing in Ethiopia. If a follow-up visit conditional on continued illness is shown to be non-inferior to current
guidelines stipulating universal follow-up, appropriate updating of such guidelines could reduce time and human
resource pressures on both providers and caregivers throughout communities of sub-Saharan Africa and South Asia.
Trial registration: This trial was registered at ClinicalTrials.gov (NCT02595827) on November 2nd, 2015
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In settings burdened with elevated under-five morbidity
and mortality, and challenged by limited access to health
care services, community health workers (CHWs) often
provide first-level care for sick children aged 2–59
months directly in the community through the imple-
mentation of integrated community case management
(iCCM) of common childhood illnesses. Current World
Health Organization (WHO) iCCM guidelines prescribe
that a febrile child presenting to a CHW be assessed for
malaria, pneumonia, and diarrhea, and for general dan-
ger signs (e.g. child is unable to drink or breast feed, is
vomiting everything, is having convulsions, is lethargic
or unconscious, and/or has chest in-drawing). CHWs
provide direct treatment for confirmed malaria, diarrhea,
and pneumonia, and, if any danger sign is present, refer
the child immediately to a health center for more exten-
sive care. However, when a febrile child has none of the
aforementioned illnesses or danger signs, the CHW pro-
vides the child with an antipyretic and advises the care-
giver to return to the CHW for a follow-up consultation
on Day 3 [1].
Such uncomplicated childhood febrile illnesses are
common, are often due to viruses, and in many cases re-
solve rapidly and spontaneously (i.e. often within 48 h,
and almost always within 96 h) [2–5]. In a study of 986
mRDT-negative children at rural health facilities in
coastal Tanzania randomized to receive or not receive
anti-malarials only 24 (2.4%) developed malaria; investi-
gators identified only 3 cases of bacteremia and 1 case of
urinary infection, along with 238 viral pathogens in stool
and/or nasopharyngeal swabs [6]. There were no severe
adverse events related to untreated illness, and no
deaths. Among 1000 children presenting with fever at
outpatient clinics in another study in both urban and
rural mainland Tanzania, 71% had viral infections, and
in most children the fever was self-limiting [7]. A ran-
domized controlled cross-over study in Tanzania sup-
ported the safety of withholding artemisinin-based
combination therapy (ACT) to mRDT negative patients
receiving care in the community [8] and a study in
Zambia found that only 8.2% of mRDT-negative children
treated in the community with an antipyretic alone con-
tinued to have fever or were reported by the caregiver to
be unwell at the time of the follow-up visit (day 5–7) [9].
These results suggest that in cases of febrile illness
among children without danger signs, and with no other
obvious cause of fever, expectant management at home
can be safely used without a follow-up visit to the CHW
on Day 3.
Therefore, current guidelines instructing CHWs to
universally advise caregivers of children with uncompli-
cated fever to return on Day 3, even in the absence of
continued fever or other signs, may be unwarranted andmay create a substantial additional burden on CHW and
caregiver time and resources. The extensive iCCM
package that is delivered by CHWs, who are often vol-
unteers, leads to a substantial workload and opportun-
ity costs (i.e. limited time available to spend on
income-generating activities). Caregivers often have to
travel long distances by foot to reach a CHW, prevent-
ing them from engaging in income-generating activities
as well.
One possible change to the current guidelines would
have the child’s caretaker advised to return with the
child for reassessment only in instances where signs per-
sist or worsen. In order to provide the evidence base for
such an update to global iCCM guidelines, we have de-
signed a cluster-randomized, community-based trial to
examine the non-inferiority of reassessment of RDT-
negative febrile children without danger signs only in
cases where signs do not resolve, compared with univer-




The primary aim of this study is to determine if the like-
lihood of clinical deterioration (“failure”) among children
between 2–59 months of age in Tanganyika Province,
DRC that present with an uncomplicated fever to CHWs
is similar between those advised universally to be
followed up on Day 3 and those advised for follow up
only if illness does not resolve. At seven days post-
enrollment, children are considered as “failed” if they
present with persistent fever, persistent illness, or decline
of health status (e.g. hospitalization, presenting danger
signs, or death). We hypothesize that the proportion of
children that meet this primary outcome determination
under current guidelines (“universal”) is 5% and that the
true rate of failure in the condition under study (“condi-
tional”) is 6%. The null hypothesis is that the conditional
follow-up approach is inferior and that children in this
group will yield a failure rate at least 4% higher than that
of the universal follow-up group. Conditional follow-up
will be considered non-inferior to universal follow up if
the upper bound of a one-sided 95% confidence interval
around the absolute difference in outcome rate (condi-
tional follow up minus universal follow up) does not ex-
ceed 4%.
Secondary aims of the study include describing the
clinical presentation, care-seeking patterns, and out-
comes among children that are classified as “failed” at
Day 7, estimating the frequency of scheduled and spon-
taneous visits among all children, hospitalization and
death rates among all children, and longer-term out-
comes (based on data collected during Day 14 and Day
28 house visits) of children that were classified as
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study with a limited sample size will look at CHWs’ and
caretakers’ perceptions of the conditional vs. universal
follow-up message.
Enrollment for this study was initiated in October
2015 and will be completed by the end of 2016. The
study is a collaboration between the International Res-
cue Committee (IRC) and the Johns Hopkins Bloomberg
School of Public Health.
Study site and population
This study is implemented in Tanganyika Province in
the southeastern DRC. With a density of 18 inhabitants
per square kilometer, Tanganyika has endemic malaria
transmission and low access to health care services due
to geographic barriers and a lack of financial resources
of those seeking care. To address these barriers, the
International Rescue Committee (IRC), with Ministry of
Public Health oversight, is currently implementing the
Canadian International Development Agency-funded
and WHO-administered Rapid Access Expansion (RAcE)
program, a 4-year effort to train and deploy CHWs to
deliver iCCM across six countries, including in 11 health
zones in Tanganyika Province. Burden of fever in this
setting is high: 2014 RaCE program data indicate that
CHWs in seven of the health zones evaluated a total of
79,000 cases of fever in children under five, 13,000 of
whom were mRDT negative.
The non-inferiority trial is being conducted in two
RaCE-participating health zones with a total under-five
population of ~168,000 (Kalemie and Nyemba, under-
five populations of 94,000 and 74,000, respectively).
Within each zone, 14 health areas are included, each
having both a health center, and a team of associated
CHWs (total 258; approximately 5–10 per area; average
104 (±81) children per CHW) who work within that par-
ticular health area. The CHWs are men and women with
at least primary school education level, who are literate
and locally resident, elected by the community, and have
received five days of training on the iCCM algorithm
as per DRC Ministry of Public Health guidelines. Med-
ications (e.g. ACT, amoxicillin, oral rehydration solu-
tion (ORS), zinc, paracetamol, and ACT suppository
for severe malaria cases requiring referral) and sup-
plies are distributed to CHWs on a monthly basis, and
the care they provide to children in their community
is free of charge.
Randomization
The unit of randomization in this trial is the health area
(n = 28), and CHWs working within a particular health
area are thus allocated to the same group (either “uni-
versal” or “conditional” follow-up advice given to care-
takers of eligible children); all children enrolled byCHWs within a health area constitute the study cluster.
Allocation to the “universal” versus “conditional” arm
was done via restricted randomization whereby units
were balanced on zone and health area estimates of 1)
population size, 2) prior 6-month likelihood of mRDT-
negative febrile children (number of children mRDT
negative/under-five population), and 3) geographic dis-
tance from CHW to zonal health center. Of all possible
randomization sequences (n = ~40.1 million, generated
using STATA version 13.1), 43,504 sequences were bal-
anced on zone and had ratios of the above three indi-
cators between 1/1.05 and 1.05. After confirming the
validity of the restriction procedure (approximately
equal probability of any two units being assigned to the
same or different arms), one of these sequences in the
restricted subset was selected at random. It was not
possible to mask the clustered allocation from partici-
pants, CHWs, or data collectors).
Sample size
To calculate sample size, we set the outcome rate in the
“universal” follow-up group to 5%, and assumed that the
(true) corresponding outcome rate in the “conditional”
follow up group is no more than 6%. For the purposes of
concluding that the “conditional” follow up is non-
inferior to the “universal” follow up approach, using
the simple approach outlined by Blackwelder [10] and
extending the methods of Hayes and Bennett [11], we
first estimated the coefficient of variation (k) of the
true failure rate across our available health areas; we
conservatively estimated that k is 0.35, implying that
the true cluster-specific failure rates vary between 1.5
and 8.5% (i.e. 5%*(1 ± 2 k)). Next, utilizing data from
the first six months of 2015, aggregated from monthly
reports from CHWs working in Kalemie and Nyemba
health zones, we anticipated that approximately 493
negative mRDT cases would occur per month over 28
health areas. We estimated that about 70% of these
mRDT negative cases would be eligible (i.e. excluding
those cases with danger signs or other CHW treatable
conditions [pneumonia, diarrhea]). Given the above
assumptions, and desiring 12 complete months of en-
rollment, the estimated average cluster size over that
anticipated timeframe is equal to (70%*493*12)/28 =
148. Assuming that about 10% of the eligible children
will not participate or will be lost to follow up (redu-
cing this yield to 148*.09 = 133, the total number of
health areas required to detect (with 80% power) non-
inferiority of the “conditional” follow up approach
given the above parameters was 24, (12 per group). Ra-
ther than exclude just 4 of our available 28 health
areas, we decided to include all 28, increasing the num-
ber of clusters to 14 per group (this increased our esti-
mated power to 86.8%), and leading to an initial
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proximately 6 months of actual study enrollment,
however, our actual observed per-cluster yield had in-
creased to 152, leading to a revised estimate of the
total enrollment; by the completion of the enrollment
period, we will enroll approximately 4270, or 2135
children per group.Eligibility and intervention
All CHWs were trained on the study protocol including
the appropriate follow up message for children with un-
complicated fever depending on study arm allocation,
and the eligibility criteria for study inclusion. CHWs
identify eligible children while conducting routine iCCM
services in their communities. Assessment of children
presenting for care under iCCM guidelines includes
examining the child, asking the caregiver about signs of
illness (e.g. danger signs, diarrhea, fever, cough, screen-
ing the child for malnutrition by measuring the mid-
upper arm circumference [MUAC] of the child), and
(rapid) testing for malaria. Some reported signs (such as
cough or difficulty breathing) will prompt the CHW to
look for chest in-drawing and measure respiratory rate.
Children ineligible for this study are those the CHW
determines to have one or more danger signs and/or
malaria, pneumonia, or diarrhea; those with danger signs
are immediately referred to the nearest health centers,
while the others are treated and advised to return on
Day 3. The remaining febrile children (i.e. those with
neither danger signs nor a CHW-treatable illness) are
eligible for enrollment. Such eligible children are pro-
vided an antipyretic and caretakers are advised if signs
should worsen in the coming days, they should immedi-
ately seek care at the health center. Finally, the CHW
provides study-arm specific advice about when to return
for a follow up visit:
1. In the “universal” study arm, CHWs advise all
caregivers to come back with the child on Day 3.
2. In the “conditional” (intervention) study arm, CHWs
advise caregivers to come back with the child on
Day 3 only if signs remain the same, or worsen.
Caregivers are told that if they determine that the
child is in good health, they do not need to return.Consent and enrollment
The CHW notifies his/her health area data collector
about the identification of the eligible child. On Day 7
after identification, the data collector and the CHW
jointly visit the child’s household to formally conduct
an oral informed consent process, enroll the child,
conduct the day 7 assessment, and record outcome
and covariate data.Upon first arriving at the home, the data collector
reads aloud a consent script explaining the study, the
CHW assessment procedures, and data collection activ-
ities, and answers any questions the caregiver might ask.
If the caregiver verbally agrees to study participation, the
data collector records vital status, axillary temperature,
respiratory rate, and MUAC, and the CHW follows the
iCCM algorithm to assess the child and query the care-
giver about the child’s signs. Specifically, the CHW asks
the mother if the child has cough, fever, diarrhea or any
problem, and assesses the child for danger signs (unable
to drink or breastfeed, vomiting everything, convulsions,
loss of consciousness, chest-in drawing), warning signs
(low MUAC, persistent illness, difficulty breathing/
wheezing, signs of possible anemia), signs of malnutri-
tion (visible signs of wasting, edema of lower limbs), and
other signs (diarrhea, with or without blood in stool,
generalized rash, and mother’s report of fever). In the
event of reported fever by the caregiver, the CHW will
check for malaria using a mRDT (and provide treatment,
as necessary); if cough is reported by the caregiver the
CHW will count the child’s respiratory rate to assess
pneumonia. The data collector records all information
from the assessment and also administers a structured
questionnaire to elicit information on infant, maternal/
paternal, and household variables, as well as on care-
seeking behaviors.
Finally, information about the child’s initial visit to the
CHW and any interim visits to the CHW (i.e. between
identification of eligibility and the Day 7 assessment
visit) is extracted by the data collector from the CHWs
iCCM records. This extraction process provides an add-
itional opportunity for the data collector to confirm that
the initial eligibility assessment by the CHW was cor-
rectly done; permission to extract this information from
the iCCM records is included in the consent process de-
scribed above.
Follow up of sick children
If the caregiver reports that the child has a fever, or if
the CHW determines that the child has any danger
signs, or has to be treated for malaria, diarrhea, or pneu-
monia during the follow up visit on Day 7 (i.e. child
meets the primary outcome definition), an additional fol-
low up visit is planned on Day 14 for the child. At this
second home visit, the CHW and data collector again
conduct the same health assessment as described above
and the outcome of the visit is recorded. As before, if a
child at a Day 14 visit is determined to have fever, any
danger sign, or one of the three CHW-treatable illnesses,
the appropriate treatment and/or or referral advice is
provided, and a third visit is scheduled for Day 28. Thus,
sick children are followed up at Day 14, and Day 28, if
necessary. The vital status (alive/died) of all enrolled
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initial enrollment, regardless of number of follow up
visits conducted.
Quality control and supervision
In order to ensure that all eligible children are correctly
identified, data collectors check the registers of CHWs
in the health area where they work on a weekly basis.
Quarterly meetings are organized for all data collectors
and research support staff to provide feedback based on
the data collected, to address challenges experienced by
the data collectors in the field and to identify best prac-
tices. In addition, each data collector receives a quarterly
individual supervision visit in the health area where
(s)he works. During this visit, the Research Manager ac-
companies the data collector on a Day 7 visit to observe
and evaluate the data collector while at work and to pro-
vide coaching and feedback in order to strengthen the
data collector’s capacities. In addition, the Research
Manager conducts spot checks of CHW registers work-
ing in the data collector’s health area during the individ-
ual supervision visit to ensure that all eligible children
are identified by the CHWs and data collectors.
Data management
All data are collected on paper forms by data collectors.
Data collectors use an extraction form to transfer infor-
mation from the CHWs iCCM records (i.e. register, indi-
vidual sick child form) for the enrolled child. Other
forms are filled out during household visits with enrolled
children on Day 7, and, if necessary, on Day 14 and Day
28. Each enrolled child receives a unique six-digit code
(“case id”) in order to ensure a linked chain of forms, as
well as to protect the child’s and caregiver’s identity.
Forms are checked for accuracy and completeness by
the Research Manager and a Data Officer prior to data
entry in Kalemie. All data forms are double-entered into
a secure online database (REDCap) [12] using custom-
ized data entry screens, with built-in validation checks.
De-identified analytic files are constructed from the raw
REDCap database files.Analysis
All children enrolled and providing available data from
the follow-up visit on Day 7 will be included in the ana-
lysis. First, we will present descriptive information on
the recruitment, enrollment, and follow up of children
with uncomplicated fever using a participant flowchart
(Fig. 1). We will then assess characteristics of enrolled
children to determine the extent to which our
randomization procedure at the health area level
achieved balance across the study arms; these character-
istics will include infant, maternal/paternal, household,and socio-economic variables. Variables that are imbal-
anced will be noted for possible inclusion in a subse-
quent adjusted analysis.
The next stage of the analysis will focus on the pri-
mary outcome, failure at Day 7 visit, which is defined as
fever, diarrhea, pneumonia or decline of health status
(e.g. hospitalization, presenting danger signs, or death).
In each study arm, the failure proportion will be esti-
mated as the number of children that “failed”, and the
non-inferiority of the two approaches to follow up
advice (“universal” vs “conditional”) will be assessed by
comparing these proportions across the two groups. The
difference in these rates (proportion of children that
failed in the conditional follow-up group minus propor-
tion of children that failed in the universal follow-up
group) along with a one-sided 95% confidence interval
will be estimated. If the upper bound of this confidence
interval is less than 0.04, we will reject the null hypoth-
esis and conclude that the conditional follow-up ap-
proach is not inferior to the universal follow-up
approach. If we have noted variables that are imbalanced
across the allocation groups, we will conduct adjusted
analyses of the difference in proportion using multivari-
ate binomial regression models with an identity link
function. A priori specified sub-analyses will include
those where the women and CHWs both report provid-
ing the per-protocol advice, those where fever is
detected based on axillary temperature (rather than
caregiver’s report), and stratified by number of days of
fever reported (>2 vs < =2). Secondary outcomes de-
scribed previously will be examined using descriptive
analytic approaches.
Monitoring
An 3-person Data Monitoring Committee was formed to
periodically receive from investigators updates on enroll-
ment progress and numbers of deaths and hospitaliza-
tions. As the invention consisted of a change in follow-
up schedule only, and all participants received usual care
(i.e. followed iCCM guidelines) from CHWs at follow up
visits, there was no formal interim analyses conducted
for safety, efficacy, or futility.
Discussion
This study, expected to be completed by the end of
2016, is a cluster-randomized, community-based non-
inferiority trial evaluating conditional follow up versus a
universal follow up of children who present uncompli-
cated fever and seek care at a CHW site. The results
from this study will provide an evaluation of the clinical
deterioration (“failure”) of children between 2 and 59
months of age that presented with an uncomplicated
fever to a CHW and subsequently received universal ver-
sus conditional follow up. Furthermore, the results from
Fig. 1 Trial design flowchart
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ical presentation, care-seeking patterns, and outcomes
among children that are classified as “failed” at Day 7,
the frequency of scheduled and spontaneous visits
among all children, hospitalization and death rates
among all children, and longer-term outcomes (based
on data collected during Day 14 and Day 28 household
visits) of children that were classified as “failed” at
Day 7.
If the conditional follow up of children with uncom-
plicated fever is shown to be non-inferior to the current
WHO iCCM protocol prescribing universal follow up
of children with uncomplicated fever by CHWs, this
will suggest that current guidelines can be simplified,
having significant implications for community-basedcase management of uncomplicated fever in the DRC,
and in many other settings. Simplification of the
current iCCM algorithm by recommending a condi-
tional follow up for children with uncomplicated fever
will reduce unnecessary follow-up visits and reduce the
burden on both CHWs and caregivers. Results will be
interpreted in conjunction with a similarly designed
trial testing the same hypothesis being conducted con-
currently in Ethiopia.
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